Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeVRSV vaccine in healthy adults
NCT03473002Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2018
- Primary completion
- Feb 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SeVRSV in respiratory syncytial virus infection (RSV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Occurrence of clinical safety laboratory abnormalities at 7 days. Started May 2018; status: completed.
02
Drugs
SeVRSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03473002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473002.